Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 151 - 184 av 184 resultater
Tid
Selskap
Tittel
Sektor
Kategori
15 Jun 2022
07:00 CEST
BIOCARTIS
Press release Biocartis Group NV: Biocartis Reaches Key Commercial Milestones: One-Millionth Idylla™ Cartridge Sold and 2,000th Idylla™ Instrument Placed
20101025 Health Services
Commercial results
15 Jun 2022
07:00 CEST
BIOCARTIS
Persbericht Biocartis Group NV: Biocartis bereikt belangrijke commerciële mijlpalen: één miljoenste Idylla™ cartridge verkocht en 2.000ste Idylla™ instrument geplaatst
20101025 Health Services
Commercial results
13 May 2022
17:40 CEST
BIOCARTIS
Press release Biocartis Group NV: Results of the Annual Shareholders’ Meeting held on 13 May 2022
20101025 Health Services
General meeting / Board Meeting
13 May 2022
17:40 CEST
BIOCARTIS
Persbericht Biocartis Group NV: Resultaten van de gewone algemene aandeelhoudersvergadering gehouden op 13 mei 2022
20101025 Health Services
General meeting / Board Meeting
04 May 2022
07:00 CEST
BIOCARTIS
Press release Biocartis Group NV: New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods
20101025 Health Services
Commercial results
04 May 2022
07:00 CEST
BIOCARTIS
Persbericht Biocartis Group NV: Nieuwe studie geleid door Memorial Sloan Kettering Cancer Center (NY, VS) toont dat Idylla™ GeneFusion Assay snellere screening van gerichte genfusies toelaat in vergelijking met routinemethoden
20101025 Health Services
Commercial results
25 Apr 2022
07:00 CEST
BIOCARTIS
Press release Biocartis Group NV: Biocartis Announces Presentation of Three Idylla™ Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
20101025 Health Services
Commercial results
25 Apr 2022
07:00 CEST
BIOCARTIS
Persbericht Biocartis Group NV: Biocartis kondigt presentatie van drie Idylla™ studies aan op 32ste Europees Congres voor Klinische Microbiologie & Infectieziekten (ECCMID)
20101025 Health Services
Commercial results
21 Apr 2022
08:00 CEST
BIOCARTIS
Press release Biocartis Group NV: Biocartis Reports Results of First Quarter of 2022: On Track to Deliver on Full-Year Guidance, Gross Margin on Products of 35%
20101025 Health Services
Commercial results
21 Apr 2022
08:00 CEST
BIOCARTIS
CORRECTIE TITEL: Persbericht: Biocartis rapporteert resultaten 1e kwartaal 2022: Op schema voor behalen vooropgezette jaardoelstellingen, brutomarge op producten van 35%
20101025 Health Services
Commercial results
21 Apr 2022
07:01 CEST
BIOCARTIS
Persbericht Biocartis Group NV: Biocartis kondigt presentatie aan van eerste prospectieve data uit valideringsstudie Merlin Test door partner SkylineDx op EADO 2022 conferentie
20101025 Health Services
Commercial results
21 Apr 2022
07:01 CEST
BIOCARTIS
Press news Biocartis Group NV: Biocartis Announces Presentation of First Prospective Validation Study Data of Merlin Test by Partner SkylineDx at EADO 2022 Conference
20101025 Health Services
Commercial results
21 Apr 2022
07:00 CEST
BIOCARTIS
Persbericht Biocartis Group NV: Biocartis rapporteert resultaten eerste kwartaal 2022: Op schema voor het behalen van de vooropgezette jaardoelstellingen, brutomarge op producten van 3%
20101025 Health Services
Commercial results
21 Apr 2022
07:00 CEST
BIOCARTIS
Press release Biocartis Group NV: Biocartis Reports Results of First Quarter of 2022: On Track to Deliver on Full-Year Guidance, Gross Margin on Products of 35%
20101025 Health Services
Commercial results
12 Apr 2022
07:00 CEST
BIOCARTIS
Press release Biocartis Group NV: Invitation to the Annual Shareholders’ Meeting
20101025 Health Services
General meeting / Board Meeting
12 Apr 2022
07:00 CEST
BIOCARTIS
Persbericht Biocartis Group NV: Oproeping tot de Gewone Algemene Aandeelhoudersvergadering
20101025 Health Services
General meeting / Board Meeting
31 Mar 2022
07:00 CEST
BIOCARTIS
Press release Biocartis Group NV: Biocartis Announces Publication of 2021 Annual Report
20101025 Health Services
Commercial results
31 Mar 2022
07:00 CEST
BIOCARTIS
Persbericht Biocartis Group NV: Biocartis kondigt publicatie 2021 jaarverslag aan
20101025 Health Services
Commercial results
24 Feb 2022
07:00 CET
BIOCARTIS
Press release Biocartis Group NV: BIOCARTIS ANNOUNCES 2021 RESULTS AND 2022 OUTLOOK
20101025 Health Services
Commercial results
24 Feb 2022
07:00 CET
BIOCARTIS
Persbericht Biocartis Group NV: BIOCARTIS KONDIGT 2021 JAARRESULTATEN EN DOELSTELLINGEN VOOR 2022 AAN
20101025 Health Services
Commercial results
17 Feb 2022
07:00 CET
BIOCARTIS
Press release Biocartis Group NV: BIOCARTIS ANNOUNCES 2021 FULL YEAR RESULTS ON 24 FEBRUARY 2022
20101025 Health Services
Other subject
17 Feb 2022
07:00 CET
BIOCARTIS
Persbericht Biocartis Group NV: BIOCARTIS KONDIGT 2021 JAARRESULTATEN AAN OP 24 FEBRUARI 2022
20101025 Health Services
Other subject
08 Feb 2022
07:00 CET
BIOCARTIS
Press release Biocartis Group NV: Biocartis and Ophiomics to Collaborate on Liver Cancer Test
20101025 Health Services
Commercial results
08 Feb 2022
07:00 CET
BIOCARTIS
Persbericht Biocartis Group NV: Biocartis en Ophiomics gaan samenwerken op test voor leverkanker
20101025 Health Services
Commercial results
04 Feb 2022
07:00 CET
BIOCARTIS
Persbericht Biocartis Group NV: Openbaarmaking van een transparantiekennisgeving
20101025 Health Services
Other financial transaction
04 Feb 2022
07:00 CET
BIOCARTIS
Press release Biocartis Group NV: Disclosure of a transparency notification
20101025 Health Services
Other financial transaction
25 Jan 2022
07:00 CET
BIOCARTIS
Persbericht Biocartis Group NV: Grote UK studie toont dat snelle EGFR testing met Idylla™ naast NGS potentieel gezondheidsresultaten van longkankerpatiënten kan verbeteren
20101025 Health Services
Commercial results
25 Jan 2022
07:00 CET
BIOCARTIS
Press release Biocartis Group NV: Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes
20101025 Health Services
Commercial results
10 Jan 2022
07:00 CET
BIOCARTIS
Persbericht Biocartis Group NV: BIOCARTIS BEHAALT BELANGRIJKSTE 2021 DOELSTELLINGEN
20101025 Health Services
Commercial results
10 Jan 2022
07:00 CET
BIOCARTIS
Press release Biocartis Group NV: BIOCARTIS MEETS 2021 KEY OBJECTIVES
20101025 Health Services
Commercial results
09 Dec 2021
07:00 CET
BIOCARTIS
Press release Biocartis Group NV: Biocartis’ Idylla™ SARS-CoV-2 testing Successfully Detects Omicron Variant
20101025 Health Services
Commercial results
09 Dec 2021
07:00 CET
BIOCARTIS
Persbericht Biocartis Group NV: Biocartis’ Idylla™ SARS-CoV-2 testing detecteert met succes de omicron variant
20101025 Health Services
Commercial results
30 Nov 2021
17:40 CET
BIOCARTIS
Press release Biocartis Group NV: SeptiCyte® RAPID Receives 510(k) clearance by US FDA
20101025 Health Services
Commercial operations
30 Nov 2021
17:40 CET
BIOCARTIS
Persbericht Biocartis Group NV: SeptiCyte® RAPID krijgt 510(k) clearance van de US FDA
20101025 Health Services
Commercial operations
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
2
3
4
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva